Claims for Patent: 7,662,552

Summary for Patent: 7,662,552

Title:	Method of diagnosing and treating lesion of crystalline lens using human CRYGS gene and coding product thereof
Abstract:	The method of diagnosing lesions of crystalline lens such as cataract is disclosed. It comprises detecting variation of crygs gene, transcript and/or protein of individuals compared with normalty. The individual suffers from cataract more possible than normalty when occurring the variation. The present invention also discloses the method and pharmaceutical composition of treating lesions of crystalline lens such as cataract.
Inventor(s):	Kong; Xiangyin (Shanghai, CN), Bu; Lei (Shanghai, CN), Zhao; Guoping (Shanghai, CN), Yan; Shunsheng (Shanghai, CN), Jin; Meilei (Shanghai, CN), Sulitang; Yerjiang (Shanghai, CN), Jin; Yiping (Shanghai, CN), Hu; Liandian (Shanghai, CN)
Assignee:	Shanghai Institutes of Biological Science, Chinese Academy of Sciences (Shanghai, CN)
Application Number:	10/362,817
Patent Claims:	1. A method for determining the cataract susceptibility in a subject comprising the steps of: a) obtaining a biological sample from said subject, said biological sample comprising nucleic acids from the subject; b) detecting in said nucleic acids the subject's gamma-S crystalline (CRYGS) gene and determining the nucleic acid sequence of the subject's gamma-S crystalline (CRYGS) gene; c) detecting in the nucleic acid sequence of the subject's gamma-S crystalline (CRYGS) gene homozygous nucleotide content comprising: i) a C at position 424 of SEQ ID NO: 30 resulting from a G to C change at position 76 of intron 1; ii) a G at position 357 of SEQ ID No: 31 resulting from an A to G change at position 11 of intron 2; iii) the sequence ATGTATGT, wherein the first position of the sequence is at position 366 of SEQ ID NO: 31, resulting from a repeat of the ATGT sequence at positions 20-23 of intron 2; and iv) an A at position 1398 of SEQ ID NO: 31 resulting from a G to A change at position 225 of exon 3; wherein said subject is a mouse and said nucleoticle content indicates an increased cataract susceptibility. 2. The method of claim 1, wherein the CRYGS gene is detected with a primer or probe. 3. The method of claim 2, wherein the primer or probe detects a difference selected from the group consisting of: i) a C at position 424 of SEQ ID NO: 30 resulting from a G to C change at position 76 of intron 1; ii) a G at position 357 of SEQ ID NO: 31 resulting from an A to G change at position 11 of intron 2; iii) the sequence ATGTATGT, wherein the first position of the sequence is at position 366 of SEQ ID NO: 31, resulting from a repeat of the ATGT sequence at positions 20-23 of intron 2; and iv) an A at position 1398 of SEQ ID NO: 31 resulting from a G to A change at position 225 of exon 3.

Details for Patent 7,662,552

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-08-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-08-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-08-25